Companies such as Henlius, OriCell, CStone, Gracell and Junshi presented clinical data from their PD-(L)1, cell therapy and other candidates. Henlius impresses with ES-SCLC data, Junshi boasts BTLA-targeted drug and OriCell flaunts GPRC5D-directed CAR-T
TCRCure said it has secured over RMB 300 million from investors to advance and expand its cell therapy pipeline, and to support the simultaneous development of its programs in the U.S. and China. More news from CellOrigin, SciNeuro, Legend Biotech, CellOrigin, SciNeuro, Legend Biotech, Signature Biotech, Neuragen and MingMed.
After launching the first CAR-T therapy on China market, Richard Wang wants to stay on the R&D frontier to push for safer, more affordable and efficacious cell therapies for more patients with the iPSC-CAR-NK technology. To succeed, emphasizing innovation and CMC early on is key, he told PharmaDJ.
At the 2021 China Cancer Immunotherapy Workshop, Wang Tao from China’s CDE and Jia Yuxia from the U.S. FDA each shared the Chinese and U.S. regulators’ considerations when reviewing new therapies. Wang said the CDE emphasizes clinical value to address unmet medical needs, while Jia explained the FDA’s clinical assessment for cell therapy.
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.